• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

NHS - Articles and news items

cost-effective cdf pills and money

NICE says Bayer’s liver cancer drug is not cost-effective

Industry news / 24 August 2016 / The National Institute for Health and Care Excellence (NICE)

NICE originally published guidance in 2010 which said that sorafenib was not cost effective but it was then made available through the CDF. NICE is reconsidering sorafenib as part of its programme to appraise drugs that are currently available…

cost effective cancer drug

NICE says Novartis’ and Janssen’s cancer drugs are not cost effective

Industry news / 18 August 2016 / The National Institute for Health and Care Excellence (NICE)

New draft guidance advises that everolimus, for treating advanced breast cancer after endocrine therapy, and ibrutinib, for treating relapsed or refractory mantle cell lymphoma, be removed from the Cancer Drugs Fund for not being cost effective…

darunavir/cobicistat

NHS England to fund HIV treatment Rezolsta (darunavir/cobicistat)

Industry news / 30 March 2016 / Victoria White

Darunavir/cobicistat is indicated for use in combination with other antiretroviral medications, for treating adults with HIV-1…

menb

MenB vaccine Bexsero might see private uptake in the UK

Industry news / 9 March 2016 / GlobalData

The UK Department of Health’s rejection of a petition to expand the routine administration of MenB vaccine Bexsero may lead to parents and physicians to consider purchasing the vaccine themselves…

eisai

Eisai criticises NHSE for further delaying access to cancer treatments

Industry news / 26 February 2016 / Victoria White

New licensed drugs that have been denied access since May 2015 will have to wait until at least July 2016 before they can be considered for the new Cancer Drug Fund…

cancer drugs fund

Public Accounts Committee publishes report on the Cancer Drugs Fund

Industry news / 5 February 2016 / Victoria White

A Public Accounts Committee has released its recommendations for the reform of the Cancer Drugs Fund…

pprs

Pharmaceutical industry to pay £550 million in 2016 as part of the PPRS

Industry news / 22 December 2015 / Victoria White

The PPRS is a unique scheme where pharmaceutical companies agreed to contribute towards the cost of medicines, with the aim of making the latest treatments affordable for the NHS…

cancer-drugs-fund

Cancer Drugs Fund public consultation launched

Industry news / 19 November 2015 / Victoria White

The new Cancer Drugs Fund will become an instrument for the collection of important information on longer term benefits which may not be available at the time of licensing…

smc

SMC accepts six new medicines for use by NHS Scotland

Industry news / 12 October 2015 / Victoria White

The medicines accepted by the SMC include Herceptin for stomach cancer, radium 223 (Xofigo) and abiraterone (Zytiga) for prostate cancer, and nintedanib (Ofev) for idiopathic pulmonary fibrosis

cancer-drug-fund

23 drugs to be axed from the Cancer Drug Fund

Industry news / 7 September 2015 / Victoria White

The announcement follows a review that found that CDF spending would rise to around £410 million for this year – an over-spend of £70m from the budget set in April 2015…

Regorafenib

Regorafenib now available on NHS Wales for treatment of advanced GIST

Industry news / 24 July 2015 / Victoria White

Regorafenib has been recommended for use on NHS Wales as a third-line treatment for patients with advanced gastrointestinal stromal tumours (GIST).

Tegaderm

NICE recommends Tegaderm CHG dressing to reduce catheter infections

Industry news / 22 July 2015 / Victoria White

NICE has recommended the use of 3M Tegaderm CHG IV securement dressing to hold catheters in place securely, reducing the risk of catheter related infections…

 

Webinar: Different thermal analysis techniques to measure the glass transitionWATCH NOW
+ +